Form 4: Definium Therapeutics Director Acquires Shares and Options

Roger Adsett, a Director at Definium Therapeutics, Inc., reported the acquisition of 3,555 common shares and a stock option for 14,620 shares.

Summary

• Roger Adsett, a Director of Definium Therapeutics, Inc., has filed a Form 4 detailing transactions related to his beneficial ownership.
• On June 11, 2026, Adsett acquired 3,555 common shares, which represent restricted stock units (RSUs).
• These RSUs vest monthly over a period of 12 months, contingent upon continued service.
• Additionally, Adsett was granted a stock option to purchase 14,620 common shares at an exercise price of $24.11 per share.
• This stock option also vests monthly over 12 months, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine equity grants to a director rather than significant financial performance or strategic shifts.

Positives

• Director Roger Adsett has increased his direct beneficial ownership through the acquisition of RSUs.
• The company has granted stock options to a director, aligning incentives with potential future share price appreciation.

Risks

• The RSUs and stock options are subject to vesting schedules and continued service requirements, meaning they could be forfeited if service is not maintained.
• The stock option exercise price of $24.11 is significantly higher than the current market price, implying substantial future share price growth is needed for the options to be profitable.

Future Outlook

The vesting schedules for both the RSUs and stock options indicate a forward-looking incentive structure tied to continued service and potential future share price performance.

Industry Context

StockSavvy.ai notes that the issuance of RSUs and stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The issuance of equity awards to directors can dilute existing ownership over time, but also serves to incentivize management for long-term value creation.
• Employees: The structure of these grants may reflect broader compensation philosophies within the company.
• Management: Directors are incentivized to perform well to ensure vesting and potential profit from stock options.

Next Steps

• Monthly vesting of RSUs and stock options over the next 12 months, contingent on continued service.
• Potential exercise of stock options if the share price exceeds the $24.11 exercise price.

Key Dates

Keywords

Form 4, Definium Therapeutics, Roger Adsett, Director, Restricted Stock Units, RSUs, Stock Option, Beneficial Ownership, Securities Exchange Act